Bavarian Nordic has signed a joint procurement agreement with HERA, the European Commission’s Health Emergency Preparedness and Response Authority, for the supply of up to 2 million doses of the Imvanex (Jynneos) monkeypox vaccine during 2023 and 2024.
Novartis has set out how it expects biosimilars to affect its business in the coming years, identifying sales of $80bn that are open to its off-patent business and expressing confidence in the ability of some of its own products to weather the arrival...
The European Commission has extended the marketing authorization for Bavarian Nordic’s smallpox vaccine, Imvanex, to include protection from monkeypox and disease caused by vaccinia virus.
Lithuania’s life sciences industry is growing at one of the fastest rates in Europe. Ahead of BIO, Innovation Agency Lithuania explains what the country’s plans are for future growth in the area and how this is built upon students heading into STEM studies.
EU systems need to become more streamlined to help bring novel technologies to market - which would in turn encourage investment and activity in healthcare biotech, says EuropaBio as it publishes key policy recommendations for the sector.
Clinical Research Organization Veristat has acquired SLF (Solutions for Life Sciences): adding capabilities to support biotech, pharmaceutical and medtech companies.
A leader from Medicines for Europe will share with CPhI Worldwide attendees a look at medicine production and offer solutions for elevating the industry.
The global pharmaceutical industry event is returning to the real world November 9-11 this year, with online content for professionals opting not to travel.
Modifications on the regulatory framework and focus on funding schemes are the first steps on the path for healthcare systems to adapt to ATMPs’ ‘new ground’, says ARM head for Europe.
Active competition law enforcement is encouraging the pharmaceutical industry to provide more affordable medicines and promotes innovation, suggests EC report.
Chinese investors are looking abroad for technology that will provide short-term returns and long-term health benefits to its large patient population, according to Panacea Ventures partner.
Denmark played host to its first BIO Europe this week, welcoming 4,500 attendees from across the globe – including growing numbers from China and South Korea.
As an increasing number of biosimilar developers target the European market, lesser-known firms may explore alternative commercialisation strategies, says Iqvia executive.
Reluctant doctors and varying reimbursement policies are affecting biosimilar trial recruitment, experts said at the European Generics Association’s biosimilars conference in London last week.
The UK beats Finland for business opportunities according to the CEO of microbial growth system developer BioSilta, who said moving the firm to St. Ives, Cambridgeshire has improved its access to larger markets.
A recent study designed to assess biopharmaceutical innovation in
the member states of the Organisation for Economic Cooperation and
Development has found that, in terms of innovation and
biotechnology industry development, Belgium...
